
Annual report 2022
added 12-21-2024
Celyad Oncology SA Net Debt 2011-2026 | CYAD
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Celyad Oncology SA
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -38.1 M | -39.8 M | -22.9 M | -47.6 M | -99.5 M | -27.2 M | -19 M | -585 K | 116 K |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 116 K | -99.5 M | -32.7 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
AbCellera Biologics
ABCL
|
14.7 M | $ 3.54 | -0.7 % | $ 1.06 B | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
AC Immune SA
ACIU
|
-191 M | $ 3.25 | 3.83 % | $ 229 M | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
-3.44 M | - | 10.36 % | $ 9.8 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
ADC Therapeutics SA
ADCT
|
-459 M | $ 4.16 | -1.42 % | $ 105 M | ||
|
Aptorum Group Limited
APM
|
-2.77 M | $ 0.8 | 1.81 % | $ 4.36 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
argenx SE
ARGX
|
-89.9 M | $ 712.23 | 1.27 % | $ 25 B | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
Ascendis Pharma A/S
ASND
|
-195 M | $ 228.93 | -0.91 % | $ 5 B | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.39 | -6.09 % | $ 8.16 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Atea Pharmaceuticals
AVIR
|
-63.1 M | $ 6.15 | 1.57 % | $ 501 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
-206 M | $ 6.62 | -0.15 % | $ 181 M | ||
|
BioCardia
BCDA
|
212 K | $ 1.35 | 6.29 % | $ 28.6 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Athersys
ATHX
|
-27.6 M | - | 3.77 % | $ 22.4 M | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 3.58 | -0.28 % | $ 7.79 B | ||
|
Catalyst Biosciences
CBIO
|
-36.1 M | $ 11.29 | -2.51 % | $ 1.01 B | ||
|
Anika Therapeutics
ANIK
|
-46 M | $ 14.58 | 1.53 % | $ 214 M | ||
|
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
CNS Pharmaceuticals
CNSP
|
-13.6 M | $ 2.32 | -5.51 % | $ 887 K | ||
|
AVEO Pharmaceuticals
AVEO
|
-48 M | - | - | $ 521 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
-19.9 M | $ 2.69 | 1.7 % | $ 16.9 M | ||
|
Curis
CRIS
|
-17 M | $ 0.89 | 3.74 % | $ 5.61 M | ||
|
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 93.04 | 2.76 % | $ 27.2 B | ||
|
Autolus Therapeutics plc
AUTL
|
-187 M | $ 1.51 | -0.33 % | $ 385 M | ||
|
Athira Pharma
ATHA
|
-47.2 M | - | - | $ 269 M | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M |